Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Income
—
Filings
33
Unique Clients
1
Active Period
2008–2015
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Antibiotic Development to Advance Patient Treatment Act of 2013
2014 · fourth_quarter · Client: CUBIST PHARMACEUTICALS
Implementation of the Affordable Care Act of 2010 (Pub. L. 111-148), Health Care and Education Reconciliation Act of 2010 (Pub.L. 111-152), Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) Pub.L. 112-144), H.R. 919 the Safeguarding America's Pharmaceuticals Act of 2013, H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act, H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act, House Committee on Energy & Commerce 21st Century Cures initiative. Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints, antibiotic resistance, reimbursement issues for antibiotics, President's Council of Advisors on Science and Technology (PCAST) and their recent report on antibiotic resistance, LPAD (Limited Population Antibacterial Drug) proposal
Client expense: $240,000 · Firm income: —
Matched citations: H.R. 3742
Implementation of the Affordable Care Act of 2010 (Pub. L. 111-148), Health Care and Education Reconciliation Act of 2010 (Pub.L. 111-152), Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) Pub.L. 112-144), H.R. 919 the Safeguarding America's Pharmaceuticals Act of 2013, H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act, H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act, House Committee on Energy & Commerce 21st Century Cures initiative. Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints, antibiotic resistance, reimbursement issues for antibiotics, President's Council of Advisors on Science and Technology (PCAST) and their recent report on antibiotic resistance, LPAD (Limited Population Antibacterial Drug) proposal
Client expense: $240,000 · Firm income: —
Matched citations: H.R. 4187
Implementation of the Affordable Care Act of 2010 (Pub. L. 111-148), Health Care and Education Reconciliation Act of 2010 (Pub.L. 111-152), Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) Pub.L. 112-144), H.R. 919 the Safeguarding America's Pharmaceuticals Act of 2013, H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act, H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act, House Committee on Energy & Commerce 21st Century Cures initiative. Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints, antibiotic resistance, reimbursement issues for antibiotics, President's Council of Advisors on Science and Technology (PCAST) and their recent report on antibiotic resistance, LPAD (Limited Population Antibacterial Drug) proposal
Client expense: $240,000 · Firm income: —
Matched citations: H.R. 919
Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024.
2014 · third_quarter · Client: CUBIST PHARMACEUTICALS
FY 2014 Omnibus HR 3547; FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67; FY 2015 Budget, H Con Res 96 (no Senate Companion at this time) HJ Res 124 Continuing Appropriations Resolution, 2015In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs. Labor/HHS/Ed Appropriations: National Institutes of Health, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation; Food and Drug Administration Appropriations; Patent and Trademark Office Appropriations
Client expense: $450,000 · Firm income: —
Matched citations: H Con Res 96
Making further continuing appropriations for fiscal year 2014, and for other purposes.
2014 · third_quarter · Client: CUBIST PHARMACEUTICALS
FY 2014 Omnibus HR 3547; FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67; FY 2015 Budget, H Con Res 96 (no Senate Companion at this time) HJ Res 124 Continuing Appropriations Resolution, 2015In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs. Labor/HHS/Ed Appropriations: National Institutes of Health, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation; Food and Drug Administration Appropriations; Patent and Trademark Office Appropriations
Client expense: $450,000 · Firm income: —
Matched citations: H J Res 106
Continuing Appropriations Resolution, 2015
2014 · third_quarter · Client: CUBIST PHARMACEUTICALS
FY 2014 Omnibus HR 3547; FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67; FY 2015 Budget, H Con Res 96 (no Senate Companion at this time) HJ Res 124 Continuing Appropriations Resolution, 2015In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs. Labor/HHS/Ed Appropriations: National Institutes of Health, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation; Food and Drug Administration Appropriations; Patent and Trademark Office Appropriations
Client expense: $450,000 · Firm income: —
Matched citations: HJ Res 124
Antibiotic Development to Advance Patient Treatment Act of 2013
2014 · third_quarter · Client: CUBIST PHARMACEUTICALS
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; HR 3742- the Antibiotic Development to Advance Patient Treatment Act of 2013; H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014;antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort
Client expense: $450,000 · Firm income: —
Matched citations: HR 3742
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the Affordable Care Act's expansion of covered 340B entities. Support legislation increasing access to wireless technologies. FDA review process consistency and predictability. Address concerns with Medicare Independent Payment Advisory Board (IPAB).Address concerns with changes to Medicare Part B and Part D programs. Issues related to antibiotics and breakpoints. Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints; antibiotic resistance among elderly population; reimbursement issues for antibiotics. H.R. 4187, DISARM - Developing An Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014; President's Council of Advisors on Science and Technology (PCAST) and their recent report on antibiotic resistance.
Client expense: $450,000 · Firm income: —
Matched citations: H.R. 4187
Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; HR 3742- the Antibiotic Development to Advance Patient Treatment Act of 2013; H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014;antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort
Client expense: $450,000 · Firm income: —
Matched citations: H.R. 4187
HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93 In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014. Issues relating to Medicare reimbursement of antibioticsAddress concerns with Medicare Independent Payment Advisory Board (IPAB). Addresss concerns with changes to Medicare Part B and Part D programs, and 2015 Hospital Outpatient Prospective Payment System. Address concerns with Medicaid coverage of specialty drugs. Support creation of incentives for antibiotics development. Oppose changes to Medicare Advantage and Part D prescription drug benefit. Support Treat and Reduce Obesity Act.
Client expense: $450,000 · Firm income: —
Matched citations: H.R. 4187
Protecting Access to Medicare Act of 2014
2014 · third_quarter · Client: CUBIST PHARMACEUTICALS
HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93 In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014. Issues relating to Medicare reimbursement of antibioticsAddress concerns with Medicare Independent Payment Advisory Board (IPAB). Addresss concerns with changes to Medicare Part B and Part D programs, and 2015 Hospital Outpatient Prospective Payment System. Address concerns with Medicaid coverage of specialty drugs. Support creation of incentives for antibiotics development. Oppose changes to Medicare Advantage and Part D prescription drug benefit. Support Treat and Reduce Obesity Act.
Client expense: $450,000 · Firm income: —
Matched citations: HR 4302
Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024.
2014 · second_quarter · Client: CUBIST PHARMACEUTICALS
Issues related to antibiotics, breakpoints, and following bills FY 2014 Omnibus HR 3547 FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67FY 2015 Budget, H Con Res 96 (no Senate Companion at this time) In all of the above the specific issues included Medicare offsets that might be applied to prescription drugs
Client expense: $380,000 · Firm income: —
Matched citations: H Con Res 96
Making further continuing appropriations for fiscal year 2014, and for other purposes.
2014 · second_quarter · Client: CUBIST PHARMACEUTICALS
Issues related to antibiotics, breakpoints, and following bills FY 2014 Omnibus HR 3547 FY 2014 Continuing Resolution H J Res 106 PL 113-73 FY 2014 Continuing Resolution H J Res 59 PL 113-67FY 2015 Budget, H Con Res 96 (no Senate Companion at this time) In all of the above the specific issues included Medicare offsets that might be applied to prescription drugs
Client expense: $380,000 · Firm income: —
Matched citations: H J Res 106
Safeguarding America's Pharmaceuticals Act of 2013
2014 · second_quarter · Client: CUBIST PHARMACEUTICALS
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACAs expansion of covered 340B entitiesOngoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints Antibiotic resistance among elderly population Reimbursement issues for antibiotics HR 4187, DISARM, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144) S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act
Client expense: $380,000 · Firm income: —
Matched citations: H.R. 1919
Fair Debt Collection Improvement Act
2014 · second_quarter · Client: CUBIST PHARMACEUTICALS
Issues related to Medicare reimbursement of antibiotics; H.R. 4187, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms HR 3402 Protecting Access to Medicare Act of 2014 Public Law No: 113-93 In all of the above the specific issues included Medicare offsets that might be applied to prescription drugs
Client expense: $380,000 · Firm income: —
Matched citations: HR 3402
Antibiotic Development to Advance Patient Treatment Act of 2013
2014 · second_quarter · Client: CUBIST PHARMACEUTICALS
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACAs expansion of covered 340B entitiesOngoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints Antibiotic resistance among elderly population Reimbursement issues for antibiotics HR 4187, DISARM, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144) S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act
Client expense: $380,000 · Firm income: —
Matched citations: H.R. 3742
Antibiotic Development to Advance Patient Treatment Act of 2013
2014 · second_quarter · Client: CUBIST PHARMACEUTICALS
Implementation of the GAIN provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation HR 3742 the Antibiotic Development to Advance Patient Treatment Act of 2013 HR 4187 Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Client expense: $380,000 · Firm income: —
Matched citations: HR 3742
Issues related to Medicare reimbursement of antibiotics; H.R. 4187, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms HR 3402 Protecting Access to Medicare Act of 2014 Public Law No: 113-93 In all of the above the specific issues included Medicare offsets that might be applied to prescription drugs
Client expense: $380,000 · Firm income: —
Matched citations: H.R. 4187
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACAs expansion of covered 340B entitiesOngoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints Antibiotic resistance among elderly population Reimbursement issues for antibiotics HR 4187, DISARM, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144) S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act
Client expense: $380,000 · Firm income: —
Matched citations: HR 4187
Implementation of the GAIN provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation HR 3742 the Antibiotic Development to Advance Patient Treatment Act of 2013 HR 4187 Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Client expense: $380,000 · Firm income: —
Matched citations: HR 4187
Drug Supply Chain Security Act
2014 · second_quarter · Client: CUBIST PHARMACEUTICALS
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACAs expansion of covered 340B entitiesOngoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints Antibiotic resistance among elderly population Reimbursement issues for antibiotics HR 4187, DISARM, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144) S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act
Client expense: $380,000 · Firm income: —
Matched citations: S. 957
Pharmaceutical Quality, Security, and Accountability Act
2014 · second_quarter · Client: CUBIST PHARMACEUTICALS
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACAs expansion of covered 340B entitiesOngoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints Antibiotic resistance among elderly population Reimbursement issues for antibiotics HR 4187, DISARM, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144) S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act
Client expense: $380,000 · Firm income: —
Matched citations: S. 959
Making further continuing appropriations for fiscal year 2014, and for other purposes.
2014 · first_quarter · Client: CUBIST PHARMACEUTICALS
FY 2014 Omnibus HR 3547, FY 2014 Continuing Resolution H J Res 106 PL 113-73 and H J Res 59 PL 113-67, and potential Medicare offsets that might be applied to prescription drugs in all of the issues listed.
Client expense: $310,000 · Firm income: —
Matched citations: H J Res 106
Safeguarding America's Pharmaceuticals Act of 2013
2014 · first_quarter · Client: CUBIST PHARMACEUTICALS
Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care & Education Reconciliation Act of 2010 (Pub. L. 111-152), Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144), S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013, S. 959, Pharmaceutical Compounding Quality and Accountability Act,H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act, Health care reform implementation; the 340B program of the Health Resources & Services Administration (HRSA), specifically 340B drug pricing issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities. Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints; antibiotic resistance among elderly population; issues related to 340B Drug Pricing Program; reimbursement issues for antibiotics.
Client expense: $310,000 · Firm income: —
Matched citations: H.R. 1919
Antibiotic Development to Advance Patient Treatment Act of 2013
2014 · first_quarter · Client: CUBIST PHARMACEUTICALS
Implementation of the Generating Antibiotics Incentives Now (GAIN) Act provisions/Title VIII of the Food & Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation, HR 3742 - the Antibiotic Development to Advance Patient Treatment of 2013, and HR 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
Client expense: $310,000 · Firm income: —
Matched citations: HR 3742
Source: Senate LDA